Dr.AhmadDr.Ahmad مدير عام
Aspergillosis is an infection of the lungs caused by inhalation of airborne spores of the fungus Aspergillus

Aspergillosis refers to several forms of disease caused by a fungus in the genus Aspergillus. Aspergillosis fungal infections can occur in the ear canal, eyes, nose, sinus cavities, and lungs. In some individuals, the infection can even invade bone and the membranes that enclose the brain and spinal cord (meningitis).

, it usually occurs in those individuals with weakened immune systems (immunocompromised) or who have a history of respiratory ailments. Because it does not present distinctive symptoms, aspergillosis is generally thought to be underdiagnosed and underreported. Furthermore, many patients with the more severe forms of aspergillosis tend to have multiple, complex health problems, such as AIDS or a blood disorder like leukemia, which can further complicate diagnosis and treatment

Once considered particularly rare, the incidence of reported aspergillosis has risen somewhat with the development of more sophisticated methods of diagnosis and advances made in other areas of medicine, such as with the increased use of certain chemotherapeutic and corticosteroid drugs that are extremely useful in treating various types of cancer but that decrease the individual's immune response, making them more susceptible to other diseases like aspergillosis

Our advanced ability to perform tissue and organ transplants has also increased the number of people vulnerable to fungal infections. Transplant recipients, particularly those receiving bone marrow or heart transplants, are highly susceptible to Aspergillus, which may be circulating in the hospital air

Causes & symptoms
Aspergillus is a fungus that is found almost everywhere, but particularly in soil, water, decaying vegetation, and stored grain. The fungus has also been cultured from ventilation systems and may be stirred up during building renovations. The species most commonly identified in patients with confirmed disease are A. fumigatus and A. flavus.

forms of aspergillosis
Allergic bronchopulmonary aspergillosis (ABPA) is seen in patients with long-standing asthma, particularly in patients taking oral corticosteroids for a long period of time. This is usually the least serious and most treatable form

Aspergilloma refers to the mass formed when fungal spores settle into or colonize areas of the lung that have been pitted and scarred as a result of tuberculosis or prior pneumonia. There are several available treatments, although the success rate varies with each treatment

Invasive fungal infection refers to rare cases in which the fungus spreads throughout the body via the blood stream and invades other organ systems. Once established, invasive fungal infections are extremely difficult to cure and, as a result, the associated death rate is extremely high.

Aspergillosis can be quite difficult to diagnose because the symptoms, such as coughing and wheezing, if present at all, are common to many respiratory disorders. Furthermore, blood and sputum cultures are not very helpful

Other, potentially more useful, (bronchial lavage), but examining a tissue sample (biopsy) is the most reliable diagnostic tool. Researchers are currently attempting to develop a practical, specific, and rapid blood test that would confirm Aspergillus infection

Signs of ABPA include a worsening of bronchial asthma accompanied by a low-grade fever. Brown flecks or clumps may be seen in the sputum.. Elevated blood levels of an antibody produced in response to Aspergillus and of certain immune system cells may indicate a specific allergic-type immune system response

A fungal mass (aspergilloma) in the lung usually does not produce clear symptoms and is generally diagnosed when seen on chest x rays.. Hemoptysis, then, is another indication that the patient may be suffering from an aspergilloma.

In patients with lowered immune systems who are at risk for developing invasive aspergillosis, the physician may use a combination of blood culture with visual diagnostic techniques, such as computed tomography scans (CT) and radiography, to arrive at a likely diagnosis.

ABPA can usually be treated with many of the same drugs used to treat asthma, such as systemic steroids. Long-term therapy may be required, however, to prevent recurrence. Antifungal agents are not recommended in the treatment of ABPA. In cases of aspergilloma, it may become necessary to surgically remove or reduce the size of a fungal mass, especially if the patient continues to spit up blood.

In non-ABPA cases, the use of antifungal drugs may be indicated. In such cases, amphotericin B (Fungizone) is the first-line therapy. The prescribed dose will depend on the patient's condition but usually begins with a small test dose and then escalates. Less than one-third of patients are likely to respond to amphotericin B, and its side effects often limit its use. For patients who do not respond to oral amphotericin B, another option is a different formulation of the same drug called liposomal amphotericin B.

For patients who fail to respond or who cannot tolerate amphotericin B, another drug called itraconazole (Sporanox), given 400-600 mg daily, has also been approved. Treatment generally lasts about 3 months.

Two other methods of treatment are being studied: direct instillation of an antifungal agent into the lungs and administration of antifungals using a nebulizer.

Instilling or injecting amphotericin B or itraconazole directly into the lung cavity or into the fungal ball (aspergilloma) itself has been helpful in stopping episodes of hemoptysis, but not in preventing future recurrences.

preventative therapy for aspergillosis is not suggested for susceptible individuals, primarily because overuse of the drugs used to fight fungal infections may lead to the development of drug-resistant aspergillosis

in ABPA, the patient will likely respond well to systemic steroids.

Patients who require lung surgery, especially those who have problems with coughing up blood, have a mortality rate of about 7-14%, and complications or recurrence may result in a higher overall death rate. However, by treating aspergilloma with other, non-surgical methods, that risk rises to 26%, making surgery a better option in some cases

, the prognosis for the most serious form, invasive aspergillosis, is quite poor, largely because these patients have little resilience due to their underlying disorders. Death rates have ranged from about 50% in some studies to as high as 95% for bone-marrow recipients and patients with AIDS

Fungal infection by Aspergillus presents a major challenge, particularly in the patient with a suppressed immune system (immunocompromised). Hospitals and government health agencies continually seek ways to minimize exposure for hospitalized patients. Practical suggestions are minimal but include moving leaf piles away from the house

References :


  • a.kannouta.kannout عضو ماسي
    تم تعديل 2008/12/23
    thank yu very very much for the good info
    go on